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Background: Recent studies have suggested that patients treated in research-active institutions have better
outcomes than patients treated in research-inactive institutions. However, little attention has been paid to explaining
such effects, probably because techniques for mediation analysis existing so far have not been applicable to survival
data.
Methods: We investigated the underlying mechanisms using a recently developed method for mediation analysis
of survival data. Our analysis of the effect of research activity on patient survival was based on 352 patients who
had been diagnosed with advanced ovarian cancer at 149 hospitals in 2001. All hospitals took part in a quality
assurance program of the German Cancer Society. Patient outcomes were compared between hospitals
participating in clinical trials and non-trial hospitals. Surgical outcome and chemotherapy selection were explored as
potential mediators of the effect of hospital research activity on patient survival.
Results: The 219 patients treated in hospitals participating in clinical trials had more complete surgical debulking,
were more likely to receive the recommended platinum-taxane combination, and had better survival than the 133
patients treated in non-trial hospitals. Taking into account baseline confounders, the overall adjusted hazard ratio of
death was 0.58 (95% confidence interval: 0.42 to 0.79). This effect was decomposed into a direct effect of research
activity of 0.67 and two indirect effects of 0.93 each mediated through either optimal surgery or chemotherapy.
Taken together, about 26% of the beneficial effect of research activity was mediated through the proposed
pathways.
Conclusions: Mediation analysis allows proceeding from the question “Does it work?” to the question “How does it
work?” In particular, we have shown that the research activity of a hospital contributes to superior patient survival
through better use of surgery and chemotherapy. This methodology may be applied to analyze direct and indirect
natural effects for almost any combination of variable types.
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Well-conducted trials are critical to advancements in
oncology. However, such trials require patients and
healthcare providers who are willing to participate in
clinical research. The effect of participation in clinical
trials is controversially discussed in the literature. Re-
views on this effect have been published in the past, but
these have usually focused on comparisons between ‘trial
patients’ and ‘non-trial patients’ and authors have come
to conflicting conclusions [1-3].* Correspondence: rochon@imbi.uni-heidelberg.de
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reproduction in any medium, provided the orIn the last years another relevant aspect of participa-
tion in clinical trials has emerged: “Do healthcare insti-
tutions or service providers who are active in research
deliver better care and outcomes than those who do not
participate in clinical research?” [4, p. 6]. According to
Pater et al. [5], especially from the healthcare policy per-
spective, this question should be the main focus of fu-
ture research because benefit from a research-active
institution will affect many more patients than just the
small proportion of participants in clinical trials. In
addition, this issue may also be of greater importance to
patients who have to decide where to go to receive
healthcare and by whom. However, only one reviewl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ture search to identify studies addressing the relationship
between institutional research activity and patient out-
comes. The available evidence suggests that patients
benefit from being treated by practitioners or in institu-
tions participating in trials. The authors concluded that
research activity might result in better health care out-
comes, although the reason for this effect remains un-
clear. Indeed, most studies focus on answering the
pragmatic question of whether research activity has an
effect on patient outcome. However, little attention is
being paid to the explanation of such effects (“How does
it work?”, i.e. the assessment of mediation).
Since the publication of the seminal paper by Baron and
Kenny [7], testing for mediation has been an integral part
of statistical analysis in psychology. In epidemiology, both
practical and theoretical aspects of mediation have been
considered since Robins and Greenland [8]. The import-
ance of mediation is well argued in Hafeman and
Schwartz [9] where they demanded the opening of the
‘black box’ when investigating exposure-disease relation-
ships. The core element of mediation analysis is the esti-
mation of two effects: The natural direct effect of
exposure on outcome and the natural indirect effect act-
ing through a so-called mediator that is assumed to reflect
a specific causal pathway between exposure and outcome.
The total effect is the aggregate of these two effects
(Figure 1A). Specifically, the natural direct effect is the ef-
fect one would observe if the exposure could be changed
without inducing a change in the mediator. The natural
indirect effect is the effect one would observe if the medi-
ator could be changed as it would when the exposure was
manipulated (without actually changing the exposure).A B
Figure 1 Path diagrams. (A) Path diagram relating exposure A to a mediat
(B) Path diagram relating hospital research activity to two mediators and oveFor normally distributed mediators and outcomes and
in the absence of interactions or non-linear effects, nat-
ural direct and indirect effects can be estimated by a
stepwise approach based on standard linear regressions
[7]. In short, models are fitted for the outcome both with
and without the mediator, and the difference in the coef-
ficients for the exposure is taken as a measure of the in-
direct or mediated effect. In oncology, however, the
outcome of interest is often patient survival. Survival
times are known to be non-normally distributed and
typically right censored. Therefore, existing techniques
for mediation analysis are not applicable to survival data,
and several authors have shown that the linear regres-
sion approach cannot be simply translated to logistic re-
gression or proportional hazard models [10-12].
The aim of this article is to introduce a recently
developed methodology that can be used to assess medi-
ation on all outcome types including survival data, and
to use this method to explain the effects of institutional
research activity on ovarian cancer patient survival.
Methods
Patients
The study is part of an ongoing quality assurance program
(QS-OVAR) initiated in 1999 by the Arbeitsgemeinschaft
Gynaekologische Onkologie (AGO) Organkommission
OVAR, a subcommittee of the German Cancer Society.
The aim of this program is to describe the pattern and
quality of care of patients with ovarian cancer in Germany
as well as to improve their outcome. The hypothesis
is that research-active hospitals yield improved outcomes
for their patients. Research activity at hospital level is de-
fined as hospital participation in prospective clinical trialsor M and an outcome Y in presence of known baseline confounders C.
rall survival time in presence of known baseline confounders.
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groups, the AGO Study Group Ovarian Cancer (AGO-
OVAR) and the Northeastern Society of Gynecologic On-
cology (NOGGO). More specifically, all patients treated in
hospitals participating in clinical trials are compared with
all patients treated in hospitals that did not participate in
any clinical trials of the AGO-OVAR and NOGGO.
The mediation analysis of the effect of research activity
on healthcare outcomes is illustrated through QS-OVAR
2001. This study involved 165 hospitals and 476 patients
with early and advanced ovarian cancer diagnosed in the
third quarter of 2001. The primary outcome measure was
overall survival. Secondary outcomes were the receipt of
standard care with regard to surgery and chemotherapy.
Details on study design and results have been described
elsewhere [13,14]. Here, we will focus on patients with ad-
vanced ovarian cancer because most death events in QS-
OVAR 2001 occurred in patients with advanced stages Féd-
ération Internationale de Gynécologie et d'Obstétrique
(FIGO) IIB–IV, whereas only a few events were observed in
FIGO I–IIA patients. Furthermore, treatment options differ
markedly between early and advanced stage disease.
According to the German guidelines, patients with ovarian
cancer FIGO IIB and higher should receive surgery includ-
ing maximal debulking as well as chemotherapy with carbo-
platin and paclitaxel [15]. We thus considered two potential
mediators. First, ‘optimal debulking’ with postoperative
tumor residuals up to 1 cm was regarded as standard care
with respect to surgery (i.e. ‘optimal surgery’). Second, each
platinum-taxane combination was considered adherent to
treatment guidelines regarding chemotherapy (i.e. ‘optimal
chemotherapy’).
The use of data included in this study was approved
by the AGO-OVAR and the AGO Ovarian Committee.
All data was anonymized prior to analysis. The study
was approved by the Ethics Committee of the Medical
Faculty of the University of Heidelberg, Germany (study
number: S-446/2013).
Statistical analyses
All analyses were conducted in R version 3.0.2 [16].
Continuous data were summarized with median and inter-
quartile range (IQR), categorical data by counts and
percentages. Survival curves were generated by the Kaplan-
Meier method. The Cox proportional hazards model with
robust variance estimator was used to assess the relationship
between hospital participation in clinical trials and overall
survival. Logistic regression models were fitted for ‘optimal
surgery’ and ‘optimal chemotherapy’ with generalized esti-
mating equations to account for clustering of patients within
hospitals. The following patient and disease characteristics
were assumed to control for confounding: age at diagnosis
(continuous, in 5 years units), Eastern Cooperative Oncolo-
gy Group (ECOG) performance status (>1 vs. 0/1), ascites(> 500 ml vs. ≤ 500 ml), comorbidity (present vs. none), hist-
ology (serous vs. other), and grade (G 3/4 vs. G 1/2).
Mediation analysis was performed using the approach
proposed by Lange et al. [17]. This approach is based on
the counterfactual framework [18] and allows decom-
position of the total effect of a given exposure A on
the outcome Y into a natural direct effect (A→ Y in
Figure 1A) and a natural indirect effect through a medi-
ator M (A→M→ Y in Figure 1A). In case of a time-to-
event outcome Y, a binary exposure A, a binary mediator
M and a number of baseline confounders C, Lange et al.
showed that unbiased estimates for the direct and indi-
rect effect are obtained from weighted Cox regression of
the time-to-event outcome on A, A* and C using a du-
plicated data set. In the first replication A* takes the ori-
ginal value of the exposure. In the second replication A*
takes the opposite (‘counterfactual’) value of the expos-
ure. The weights are determined by Wc = P(M | A*, C) /
P(M | A, C), with P( · ) deriving from a logistic regres-
sion of the mediator M on the exposure and the baseline
confounders [17, Appx. 4]. Assuming non-informative
censoring and proportional hazards, the weighted Cox
model then yields hazard ratios for A and A* that serve
as estimates for the natural direct effect and indirect ef-
fect, respectively. The product of the two hazard ratios
yields the hazard ratio for the total effect. Standard er-
rors and confidence intervals can, for example, be deter-
mined by bootstrap methods.
In our study, we explored two binary mediators (sur-
gery and chemotherapy) of the effect of hospital research
activity on survival (Figure 1B). Under the assumption of
separate causal pathways through the two mediators, un-
biased point estimates for the natural direct effect and
the natural indirect effects related to the two mediators
were obtained by a weighted Cox regression of the out-
come on the exposure, the baseline confounders and
two additional counterfactual variables A1* and A2* that
were systematically manipulated in four replicates of the
original data [19]. Confidence intervals for mediation ef-
fects that account for clustering of patients within hospi-
tals were obtained using simple random cluster sampling
and 10,000 bootstrap simulations. In all analyses, results
were considered statistically significant if the 95% confi-
dence interval (CI) for the hazard ratio (HR) or odds ra-
tio (OR) did not include 1.
In the additional material (see Additional file 1), we
have provided a detailed description of the analysis with
the corresponding R code to enable future researchers
to assess mediation in a survival context. There, we also
show how we tested for interactions between exposure
and confounders, how we assessed the linearity assump-
tion for all variables, and how we allowed for misspecifi-
cation in the mediators. Finally, this description includes
sensitivity analyses with only one mediator representing
Table 1 Patient and disease characteristics at diagnosis
Trial hospitals Non-trial hospitals
No. of patients, N (%) 219 (62.2) 133 (37.8)
Age (years)
Median (IQR) 64 (57–73) 66 (56–74)
Performance status, N (%)
ECOG 0/1 166 (75.8) 101 (75.9)
ECOG > 1 53 (24.2) 32 (24.1)
Ascites, N (%)
≤ 500 ml 113 (51.6) 59 (44.4)
> 500 ml 106 (48.4) 74 (55.6)
Comorbidity, N (%)
None 166 (75.8) 91 (68.4)
Present 53 (24.2) 42 (31.6)
Histology, N (%)
Serous 167 (76.3) 96 (72.2)
Other 52 (23.7) 37 (27.8)
Grade, N (%)
G 1/2 97 (44.3) 69 (51.9)
G 3/4 122 (55.7) 64 (48.1)
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and chemotherapy as a binary and an ordinal variable.
Results
Altogether, two-thirds of the 476 patients diagnosed in
the third quarter of 2001 had advanced ovarian cancer.
The 352 patients with FIGO IIB or higher were treated
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Non-trial hospitals 133 109 95
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Figure 2 Kaplan-Meier survival curves in advanced ovarian cancer accranged from 1 to 12, the median number was two. 219
patients (62%) were treated in 77 hospitals participating
in clinical trials, and 133 patients (38%) were treated in
72 non-trial hospitals. However, only 59 (27%) of the
219 patients in trial hospitals were actually enrolled in
clinical trials which included a trial that did not show
any superiority of the experimental treatment [20]. Pa-
tient and disease characteristics at diagnosis for both
groups are listed in Table 1.
During the follow-up period of three years, 184 out of
352 patients with advanced ovarian cancer died. The
median overall survival time was 35 months for the 219
patients treated in hospitals participating in clinical trials
compared to 25 months for the 133 patients treated in
non-trial hospitals (Figure 2). This survival benefit
remained stable even after adjustment for all patient and
disease characteristics listed in Table 1, as well as after
adjustment for clustering of patients within hospitals in
a multivariable Cox model. The total effect of research
activity (adjusted for known confounders) can be found
in Table 2: The adjusted HR of death was 0.58 (95% CI:
0.42 to 0.79).
How much of the total beneficial effect of research ac-
tivity is mediated through optimal debulking and stan-
dard chemotherapy? In the first step, we separately
explored the relationship between hospital participation
in clinical trials and the two independent mediators. The
proportion of patients receiving the recommended
platinum-taxane combination was 70% in research-
active hospitals and 59% in non-trial hospitals (adjusted
OR = 1.64, 95% CI: 0.91 to 2.95). 66% of the 219 patients
treated in research-active hospitals had maximal tumor18 24 30 36
Months
149 129 100 43
83 63 43 15
219, Death events = 103)
133, Death events = 81)
ording to hospital participation in clinical trials.
Table 2 Multivariable Cox regression analysis for overall
survival in patients with advanced ovarian cancer
Variable N Events HR 95% CI
Research activity
Non-trial hospital 133 81 1 Reference
Trial hospital 219 103 0.58 [0.42; 0.79]
Age
Continuous (5 years) 352 184 1.24 [1.14; 1.34]
Performance status
ECOG 0/1 267 118 1 Reference
ECOG > 1 85 66 2.02 [1.38; 2.96]
Ascites
≤ 500 ml 172 74 1 Reference
> 500 ml 180 110 1.77 [1.23; 2.53]
Comorbidity
None 257 116 1 Reference
Present 95 68 1.46 [1.08; 1.97]
Histology
Other 89 40 1 Reference
Serous 263 144 1.29 [0.85; 1.94]
Grade
G 1/2 166 81 1 Reference
G 3/4 186 103 1.10 [0.80; 1.50]
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treated in non-trial hospitals (adjusted OR = 1.57, 95%
CI: 0.92 to 2.69). Altogether, about 50% of patients in
research-active hospitals and 38% of patients in non-trial
hospitals received the combination of optimal debulking
with standard chemotherapy (Figure 3).
In the next step, we explored the effect of standard
care on survival, again by means of a multivariable Cox
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Figure 3 Adherence to treatment guidelines with regard to surgery a
hospital participation in clinical trials.associated with survival. The adjusted HR of death for
optimally debulked patients was 0.46 (95% CI: 0.34 to
0.63) compared to patients with a postoperative tumor
residual larger than 1 cm. Similarly, we found a survival
benefit for patients treated with platinum-taxane chemo-
therapy (adjusted HR = 0.42, 95% CI: 0.28 to 0.62).
Finally, we used the approach of Lange et al. [17] to
test if the observed positive effect of institutional re-
search activity on patient survival is at least partially me-
diated through surgery and chemotherapy (Figure 1B).
The effects of hospital participation on overall survival
in terms of natural direct and indirect hazard ratios can
be summarized as follows (Table 3): The total HR of 0.58
was decomposed into a direct HR of research-activity of
0.67 (95% CI: 0.47 to 0.92) and an indirect HR for both
mediators of 0.87 (95% CI: 0.75 to 0.98). The indirect HR
with regard to surgery alone was 0.93, the corresponding
indirect HR with respect to chemotherapy was also
0.93; thus the resulting total effect was 0.67 × 0.93 ×
0.93 = 0.58. The proportion mediated through surgery
and chemotherapy was similar and was about 13% for
each mediator on the log HR scale. Altogether, about
26% of the total effect of hospital research activity on
survival was mediated through the proposed pathways
(95% CI: 3% to 69%).
Discussion
The effect of institutional research activity on patient
outcomes has not yet been investigated extensively,
despite its great relevance to healthcare providers,
policy makers, and patients. So far, only a few studies
have examined the association between patient out-
comes and institutional participation in clinical trials,
as opposed to trial participation of individual patients
[6]. Thus, the authors of the 2011 special issue of
Annals of Oncology entitled “Clinical Research and





nd chemotherapy in advanced ovarian cancer according to
Table 3 Mediation analysis: Total, direct and indirect
effects with 95% confidence intervals
Effect (of trial hospital vs. non-trial hospital) HR 95% CI
Total effect 0.58 [0.41; 0.80]
Direct effect 0.67 [0.47; 0.92]
Indirect effect (through surgery) 0.93 [0.84; 1.02]
Indirect effect (through chemotherapy) 0.93 [0.84; 1.01]
Indirect effect (through both surgery and
chemotherapy)
0.87 [0.75; 0.98]
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further research on this topic is urgently required. If
research activity has beneficial effects on patient out-
comes, these benefits are not solely restricted to re-
search participants.
Investigating the relationship between research activity
at the level of institutions or providers and outcomes at
the level of patients is not as easy as it seems at first
glance. Researchers interested in this relationship are con-
fronted with several practical challenges, such as getting
data from less research-active institutions, as well as with
several methodological challenges, for instance, the choice
of the appropriate study design [5]. In addition, sole focus
on establishing effects and measuring the potential bene-
fits of research activity on healthcare outcomes is often
considered insufficient [6]. The assessment of variables
mediating the effects may be helpful in explaining the ef-
fects of exposure or in investigating the reasons why an
exposure failed to yield an expected outcome. More im-
portantly, knowledge of such mechanisms enables specific
measures to improve healthcare at the individual level and
at the institutional level—and such measures may be im-
plemented even in the absence of exposure. Krzyzanowska
et al. [21] described a conceptual framework for under-
standing how institutional research activity might lead to
better outcomes, even for patients who are not partici-
pants in a research project. The authors pointed out that
the processes of care received by patients may have a
strong impact on outcomes and that such processes may
systematically differ between research-active and research-
inactive settings. For example, institutions that actively
participate in research may be more likely to follow clin-
ical guidelines for cancer treatment. In addition, participa-
tion in research may facilitate early access to new
treatment approaches, allowing the faster implementation
of new evidence into practice.
The main purpose of the present work was to explore
the mechanisms underlying the association between in-
stitutional research activity and patient outcomes. We
first re-examined the association between institutional
research activity and survival described by du Bois et al.
[13]. Using the data of 352 patients with advanced ovar-
ian cancer, we showed that hospital participation inclinical trials was associated with improved survival. The
effect observed in our study was large and clearly rele-
vant because of a relative reduction in the risk of death
by 42% in favor of research activity. Whether this effect
is in line with the literature is difficult to answer be-
cause, with respect to ovarian cancer, trial participation
has hardly been investigated outside Germany. Further-
more, only a few studies have examined the association
between patient outcomes and research activity at the
level of health care institutions [6].
As expected, patients with ‘optimal surgery’ and ‘opti-
mal chemotherapy’ lived longer than patients who were
not treated according to the standard of care. In
addition, patients treated in trial hospitals were more
likely to receive optimal treatment than patients treated
in non-trial hospitals. We thus confronted the question
of how much of the effect of hospital participation in
clinical trials on patient survival was mediated through
optimal debulking and optimal chemotherapy selection.
To answer this question, we used a recently developed
methodology for assessing mediation in the context of a
survival analysis [17]. Taking into account several known
baseline confounders, the overall hazard ratio (total ef-
fect) of 0.58 was decomposed into a direct effect of re-
search activity of 0.67 and two indirect effects of 0.93
each mediated through surgery and chemotherapy. The
aggregate indirect effect through both mediators was
0.87, that is, about 26% of the beneficial effect of re-
search activity was mediated through both surgery and
chemotherapy. In conclusion, trial participation of a hos-
pital contributed at least partially to a superior outcome
through the better quality of treatment provided.
The probability of surviving ovarian cancer depends
on (1) patient characteristics (e.g. age), (2) tumor biology
(e.g. stage), and (3) the quality of treatment (e.g. surgical
outcome, selection of chemotherapy regimen). The first
two factors are hard to change but the quality of treat-
ment is susceptible to direct influence and thus seems to
be of utmost relevance when considering efforts to im-
prove the outcome of this disease. The implementation
of standards into clinical routine in our study was not
satisfactory and still needs improvement; however, taken
both mediators together, treatment standards were more
strictly implemented in trial hospitals than in non-trial
hospitals. The good news is that clinicians can influence
the implementation of standards, regardless of whether
they are employed in research-active hospitals or not.
The main limitation of our study is the lack of ran-
domization of patients into research-active and research-
inactive hospitals. Such a randomized controlled trial
would facilitate a clear causal interpretation but would
also be hard to implement. When randomization is not
possible, well-conducted observational studies can provide
the necessary data to guide the future development of
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analysis can help explore the mechanisms by which re-
search activity leads to the outcome of interest. The key
assumption for mediation analysis is that all relevant con-
founders are included into the analysis. To be more pre-
cise, the approach proposed by Lange et al. [17] requires
that the considered variables are sufficient for controlling
the confounding of 1) the exposure-outcome relation, 2)
the exposure-mediator relation, and 3) the mediator-
outcome relation. We addressed this issue by incorpora-
ting all established prognostic factors into the models for
the mediator and the outcome. In particular, age at diag-
nosis, FIGO stage, ECOG performance status, volume of
ascites, histology, grade, and comorbidity are well-known
prognostic factors for survival in ovarian cancer [22-24].
These factors also influence treatment recommendations.
There must be no other variables (measured or un-
measured) that confound the mediator-outcome relation
which are themselves affected by the exposure; this last
assumption essentially ensures that each of the consi-
dered pathways between exposure and outcome does
indeed represent a unique causal mechanism. In obser-
vational studies, these assumptions are inherently un-
testable and must instead be justified by means of
knowledge about the biological processes under conside-
ration. In our study, for example, we did not collect in-
formation on socioeconomic factors (e.g. income or
insurance status). Patients with a higher socioeconomic
status (SES) may find it easier and hence choose to
travel to specialized or better rated hospitals or institu-
tions that are research-active and participate in clinical
trials. In contrast, cancer patients with a low SES may be
less likely to choose research-active hospitals because of
the lack of corresponding health care information. The
total effect of research activity would then at least be
partially due to better general survival rates of patients
with a high SES. Lower socioeconomic status has occa-
sionally been associated with lower likelihood of recei-
ving surgery and chemotherapy but does not seem to be
an independent prognostic factor for survival in ovarian
cancer [25,26].
Finally, the mediation analysis is only valid if the logistic
regressions are adequate descriptions of the mediators.
Sensitivity analyses showed that misclassification of the me-
diator will bias the estimates of the indirect effect towards
one and the direct effect away from one. In our study,
measurement error was minimized by objectively assessing
the quality of chemotherapy and by evaluating surgical out-
come (i.e. tumor residual) in a standardized manner.
Conclusions
Mediation analysis, which is regularly and successfully
applied elsewhere in health care, has a great potential to
be used as an instrument for investigating underlyingmechanisms. This tool allows analysis to go beyond the
question “Does it work?” In particular, mediation ana-
lysis has shown that the research activity of a hospital
contributes to superior patient survival through better
adherence to treatment guidelines with regard to surgi-
cal outcome and selection of chemotherapy. Yet, the
analysis of the ovarian cancer study presented in this
article demonstrates only one way of applying this
methodology, but the potential for this technique is
much wider. This methodology, which can be conducted
with standard software, may be applied to analyze direct
and indirect effects for almost any combination of variable
types (in particular, the mediator and outcome can be bin-
ary, ordinal, categorical, or continuous, and the outcome
can also be survival time). Researchers interested in the
question “How does it work?” are thus strongly encou-
raged to use mediation analysis in their investigations.
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